

Date: 2012-Jan-06

To: Centre Representatives  
Ethics Representatives  
Contact Clinical Research Associates

From: Anna Sadura, Trial Management, NCIC Clinical Trials Group

**RE: PERMANENT TRIAL CLOSURE NOTICE FOR  
PHASE I/II/III NCIC CTG LED STUDIES**

Dear Participants,

We are writing today to inform you of the results of our annual Permanent Trial Closure Assessment. This annual process includes two components: assessment of trials led by NCIC CTG and assessment of trials led by intergroup collaborators. This letter addresses the first of these components. We have identified the following NCIC CTG-led trials that are complete and no longer require action. Please find these trials listed below. "No longer require action" includes cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals. We are hopeful that the permanent closure of trials that have met all study endpoints and that no longer warrant data collection will reduce the workload for participating centres.

<i><b>Disease Site</b></i>	<i><b>Trial Code</b></i>
Breast	MA17L MA27 MA27B
Genitourinary	BL11 PR3
Hematology	HD6 LY13
Lung	BR19
Symptom Control	SC22
IND	IND162 IND166B IND173 IND179 IND181 IND182 IND183 IND185

Health Canada, NCI US, intergroup collaborators and industry partners will be notified of these final trial closures where applicable. Please notify your REB of any outstanding ethics documents for the applicable

trials above and of the final completion of these trials. A copy of this notification must be kept on file at your centre for auditing purposes. Please note that this memorandum supersedes any protocol instructions requiring the continued follow-up of patients and submission of data.

Please note that although these trials are permanently closed, trial documents must still be retained. NCIC CTG will continue to notify participating centres when trial related records no longer need to be retained in accordance with applicable regulations. Please visit the following web site for further information: <http://www.ctg.queensu.ca/private/ethics/RecordsRetention.pdf>

Soon, we will be circulating a second notice that addresses our annual review of intergroup trials that can be closed to further activity.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Anna Sadura". The signature is written in a cursive, flowing style.

Manager, Trial Conduct  
NCIC CTG Clinical Trials Group  
[asadura@ctg.queensu.ca](mailto:asadura@ctg.queensu.ca)